Emalex Biosciences

Emalex Biosciences is developing new treatments for central nervous system disorders including Tourette syndrome. 

Brain and money connected by a thread on a white background
Biotech

Teva inks $700M Emalex buyout to bag near-approval Tourette drug

Teva predicted ecopipam could become a preferred later-line therapy because it balances safety and efficacy better than existing drugs.
Nick Paul Taylor Apr 29, 2026 9:07am
Amazing landscapes of Appenzell with impressive rock formations and beautiful lakes

Emalex eyes potential Tourette approval after phase 3 win

Feb 25, 2025 1:18pm
2022 money

Biotech's top money raisers: 2022

Apr 11, 2023 9:19am
money bills fundraise

Tourette-focused Emalex rakes in $250M series D

Nov 3, 2022 7:00am